Medical assessment of adverse health outcomes in Dutch childhood cancer survivors; a nationwide project (DCOG LATER study) DCOG LATER substudy: Sexual function and psychosexual development in long-term childhood cancer survivors

Completed

• Conditions: psychosexuele ontwikkeling; sexual function and psychosexual development; 10013356; 10024450

• Registration Number: NL-OMON47606
• Lead Sponsor: Stichting Kinderoncologie Nederland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 6500

Inclusion Criteria

The general study design involves a nation-wide multicentre retrospective
cohort study including the entire DCOG-LATER cohort of CCS according to the
DCOG-LATER inclusion criteria:
1) Patients treated for childhood cancer in one of the 7 pediatric oncology
centres between 1960-2001.
2) A histological verified diagnosis of malignancy covered by the ICCC3 and
including long-term survivors of severe forms of Langerhans Cell Histiocytosis
treated with chemotherapy and/or radiotherapy.
3) Age 0-17 years at diagnosis malignancy.
4) Survival at least 5 years from diagnosis.
Additional inclusion criteria apply for the DCOG-LATER sexual function and
psychosexual development study:
1) Alive at time of study
2) Age 18 years or older
3) No severe mental retardation
4) Sufficient understanding of the Dutch language to complete the
questionnaires.

Exclusion Criteria

1) Treated for childhood cancer after 2001
2) less than 5 year survival from diagnosis
3) age at time of study less than 18 years
4) living abroad at time of study
5) mental retardation
6) insufficient knowledge of dutch language to complete questionnaires

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1. Prevalence of sexual dysfunctions<br /><br>2. Disease and treatment related risk factors for sexual dysfunctions<br /><br>3. Prevalence of distress associated with sexual dysfunction<br /><br>4. Relationship factors<br /><br>5. Prevalence of delayed psychosexual development<br /><br>6. Disease and treatment related risk factors for delayed psychosexual<br /><br>development<br /><br>7. Free Androgen Index (FAI, based on serum testosteron and sex hormone binding<br /><br>globulin levels))</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>n.a.</p><br>